Table 1.
Entry | Cpd | Structure | αvβ3 IC50 [nm][a] | Rp/n [b] |
---|---|---|---|---|
1 | 5 | cyclo[DKP‐RGD]‐Val‐Ala‐PTX (aliphatic scaffold) | 14.8±3.9 | – |
2 | 6 | cyclo[DKP‐RGD]‐Val‐Ala‐PTX (aromatic scaffold) | 27.3±9.8 | – |
3 | 7 | (cyclo[DKP‐RGD])2‐Val‐Ala‐PTX | 4.0±0.1 | 3.4 |
4 | 8 | (cyclo[DKP‐RGD])3‐Val‐Ala‐PTX | 1.2±0.5 | 7.6 |
5 | 9 | (cyclo[DKP‐RGD])4‐Val‐Ala‐PTX | 1.3±0.3 | 5.3 |
6 | 1 | cyclo[DKP‐RGD] | 4.5±0.1 | – |
[a] IC50 values were calculated as the concentration of compound required for 50 % inhibition of biotinylated vitronectin binding, as estimated by GraphPad Prism software. All values are the arithmetic mean ± the standard deviation (SD) of triplicate determinations. [b] The relative potency Rp is obtained by dividing the IC50 of the monovalent reference 6 by the IC50 of each multivalent conjugate. Rp/n values were calculated by dividing Rp of the multivalent conjugates by the valency (n) of each conjugate.22